SAN DIEGO, March 25, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Vertex, Inc. (NASDAQ: VERX). The investigation focuses on Vertex’s executive officers and whether investor losses may be recovered under federal securities laws. What if I purchased Vertex securities?If you purchased Vertex securities and suffered losses on your investment, join our investigation now: Click here to join the investigation.Or for more information, contact Jim Baker at ...

Key Takeaways VRTX stock fell 4.8% in a month amid concerns over new drugs and lack of near-term catalysts.Vertex's CF franchise drives growth, with Trikafta and Alyftrek boosting 2025 revenues by 9%.New drugs like Journavx and Casgevy show mixed uptake, while pipeline setbacks add pressure.Vertex Pharmaceuticals Incorporated (VRTX) stock has declined 4.8% over the past month. This reflects concerns over the commercial potential of its new drugs, Journavx and Casgevy, recent pipeline setbacks, and broader m ...

Vertex available on Oracle Cloud Infrastructure enables rapid deployment and advanced global tax managementKING OF PRUSSIA, Pa., March 17, 2026 (GLOBE NEWSWIRE) -- Vertex Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a leading provider of enterprise compliance technology for global commerce and an Oracle partner, today announced Vertex O Series Tax Engine and Indirect Tax Accelerator for Oracle’s ERP offerings are available on the Oracle Marketplace and can be deployed on Oracle Cloud Infrastructure (OCI) ...

Core Insights - Vertex Pharmaceuticals has successfully expanded its portfolio beyond cystic fibrosis (CF) treatments, gaining approvals for drugs targeting blood disorders and non-opioid pain management [1][2] - The company is on track to submit its candidate for IgA nephropathy, Povetacicept, for regulatory approval by the end of the month [2] Vertex's Cystic Fibrosis Leadership - Vertex is the leading player in the CF market, with a portfolio of CFTR modulators that address approximately 90% of the CF patient population [4] - The CF portfolio generated $12 billion in sales in the latest full year [5] Future Growth Potential - Vertex anticipates that non-CF drugs will generate at least $500 million this year, with each new drug potentially becoming a multi-billion-dollar opportunity [6] - The approval of Povetacicept could establish a fourth treatment franchise for Vertex, further enhancing its market presence [6] Stock Performance and Market Outlook - The current stock price is approximately $480, with a potential target of $600 representing a 25% increase in market value from $121 billion to $152 billion [8][9] - The stock is currently trading at 24 times forward earnings estimates, suggesting it is reasonably priced [10]

On February 17, 2026, Tensile Capital Management LP reported selling 384,415 shares of Vertex (NASDAQ:VERX) in the fourth quarter, an estimated $8.32 million trade based on quarterly average pricing. What Happened According to an SEC filing dated February 17, 2026, Tensile Capital Management LP sold 384,415 shares of Vertex in the fourth quarter of 2025. The estimated value of the shares sold is $8.32 million, based on the average closing price for the quarter. The quarter-end value of the stake declined ...

Core Insights - Vertex Pharmaceuticals announced positive Week 36 interim analysis results from the RAINIER Phase 3 trial of povetacicept for IgA nephropathy, achieving significant reductions in proteinuria and serum Gd-IgA1 levels compared to placebo [1][2][3] Efficacy Results - The primary endpoint showed a 52.0% reduction in proteinuria (UPCR) from baseline, with a statistically significant 49.8% reduction compared to placebo (P<0.0001) [1][2] - For the first secondary endpoint, povetacicept treatment resulted in a 77.4% reduction in serum Gd-IgA1, leading to a 79.3% reduction compared to placebo (P<0.0001) [1][2] - In patients with baseline hematuria, 85.1% achieved hematuria resolution, a 61.7% improvement compared to placebo (P<0.0001) [1][2] Safety Profile - Povetacicept was generally safe and well tolerated, with most adverse events being mild to moderate [1][2] - Serious adverse events were low, with 3.0% in the povetacicept group and 4.3% in the placebo group [2] - Treatment discontinuation rates were 3.8% for povetacicept and 8.8% for placebo [1][2] Regulatory and Development Plans - Vertex plans to complete the Biologics License Application (BLA) for povetacicept by the end of March for potential U.S. Accelerated Approval [1][2] - The FDA has granted rolling review for the BLA, which Vertex is expediting using a priority review voucher [2][3] - The RAINIER trial will continue with final analysis expected at two years of treatment, focusing on total estimated glomerular filtration rate (eGFR) slope [2][3] About Povetacicept - Povetacicept is a dual inhibitor of BAFF and APRIL cytokines, showing improved binding affinity and potency compared to other inhibitors in preclinical studies [2][3] - It has received FDA Breakthrough Therapy Designation for IgA nephropathy and is the only dual BAFF+APRIL inhibitor in pivotal trials for multiple kidney diseases [2][3] About IgA Nephropathy - IgA nephropathy is a serious kidney disease affecting approximately 330,000 people in the U.S. and Europe, with a significant risk of progression to end-stage renal disease [2][3]

Core Insights - Vertex Pharmaceuticals announced positive data from a Phase 4 study of JOURNAVX® (suzetrigine), a non-opioid pain signal inhibitor for treating moderate-to-severe acute pain in adults [1] - The study demonstrated effective pain management and facilitated opioid-free recovery following various plastic surgical procedures [1] - A significant finding was that 90.9% of patients in the study remained opioid-free by the end of treatment [1]

Company Overview - Vertex is a global provider of transaction compliance and indirect tax solutions [1] - The company serves over 60% of the Fortune 1000, indicating a strong market presence [1] - Vertex has been in operation for approximately 47 years, originally founded as an indirect tax company [1] Product Portfolio - The company has expanded its offerings to include various compliance solutions and e-invoicing [1] - E-invoicing is highlighted as a key area due to global mandates [1] Customer Base - Vertex's customer base includes a number of the largest companies in Europe, showcasing its international reach [1]

Vertex Conference Call Summary Company Overview - **Company Name**: Vertex (NasdaqGM:VERX) - **Industry**: Transaction compliance and indirect tax solutions - **Customer Base**: Over 60% of Fortune 1,000 companies, including major European firms - **Headquarters**: King of Prussia, Pennsylvania - **History**: Founded approximately 47 years ago, originally focused on indirect tax solutions, now expanded to include compliance solutions and e-invoicing [4][5] Key Points and Arguments Business Priorities for 2026 - **Core Business Strength**: Focus on compliance and tax needs for Fortune 1,000 companies [9] - **E-invoicing Mandates**: New mandates in Europe (e.g., Belgium, France, Germany) create opportunities for Vertex to expand its services [10][11] - **AI Transformation**: Internal initiatives to enhance operations and customer service using generative AI [12][13] AI Capabilities - **Internal AI Initiatives**: Improving software development, customer service, and sales processes [13] - **Customer-Facing AI Products**: Introduction of AI tools like Smart Categorization to streamline tax processes and reduce manual work [15][17] - **Expansion Beyond Retail**: Plans to extend AI capabilities to other sectors such as medical devices [22][23] Competitive Advantages - **Accuracy and Trust**: Vertex's solutions are critical for tax compliance, with a focus on accuracy and auditability [30][31] - **Proprietary Content**: Approximately 70% of tax rules are not available online, requiring Vertex's expertise to interpret and implement [31][32] - **Integration**: Deep integration with customer ERP systems enhances service delivery [34] Growth and Retention Challenges - **2025 Growth Rate**: Annual recurring revenue (ARR) growth slowed from 18% to 11% due to customer churn and lower cross-sell/upsell rates [37][38] - **Customer Retention Strategies**: Focus on improving customer support and reducing implementation times to enhance satisfaction [47][48] New Customer Acquisition - **Strong New Logo Growth**: 20% increase in new customers, with many transitioning from simpler solutions to Vertex's offerings [53][54] - **ERP Migration Opportunities**: Continued growth in SAP and Oracle ecosystems as customers migrate to cloud solutions [56][57] E-invoicing Market - **Market Adoption**: Companies are reacting to compliance mandates, often starting with a few countries before expanding globally [60][64] - **Integration with Compliance Needs**: E-invoicing is part of a broader compliance strategy, with Vertex offering integrated solutions [61][62] Financial Outlook - **2026 Guidance**: Expected growth of 10-11%, with long-term targets set for higher growth rates [59] - **Margin Improvement**: Focus on operational efficiency and AI-driven productivity to enhance EBITDA margins [68][69] Additional Important Insights - **Customer Engagement**: Direct engagement with customers is crucial for product development and understanding market needs [26][27] - **AI in Software Development**: Significant improvements in development velocity (up to 44%) due to AI tools [75] This summary encapsulates the key points discussed during the Vertex conference call, highlighting the company's strategic priorities, competitive advantages, growth challenges, and market opportunities.

Vertex Conference Call Summary Company Overview - **Company**: Vertex (NasdaqGM:VERX) - **Industry**: Technology, specifically focusing on tax compliance and automation solutions Key Points and Arguments Leadership and Background - Chris, the new leader at Vertex, has over 30 years of experience in the technology industry, particularly in cybersecurity, having held roles at Cisco, RSA Security, VMware, Intel, and McAfee [2][3][4] Customer Insights - Customers have validated Vertex's reputation for accuracy and reliability, allowing them to operate leaner tax departments [13] - There is a recognized need for Vertex to innovate and bring new capabilities to market more quickly [15] - AI tools are seen as a significant growth opportunity to enhance customer experience and operational efficiency [16] Business Performance - Vertex reported a strong new business quarter at the end of 2025, with overall business growth and increasing Annual Recurring Revenue (ARR) [19] - However, there was a 5% drop in Net Revenue Retention (NRR), attributed to customer churn and external factors like bankruptcies and mergers [24][25] - Approximately 70% of new revenue opportunities are expected to come from existing customers, emphasizing the importance of customer retention [25] AI Integration - Vertex is focusing on AI capabilities to enhance product experiences and automate manual tasks, such as tax determination processes [29][30] - The introduction of tools like Smart Categorization aims to reduce manual effort in categorizing products for tax purposes, which is currently a labor-intensive task for customers [32] E-Invoicing and Compliance - E-invoicing mandates are becoming increasingly common globally, with governments requiring real-time transmission of invoices to enhance tax compliance [50][54] - Countries like Italy, Belgium, France, and Germany are implementing e-invoicing, which is expected to drive demand for Vertex's solutions [54][55] - E-invoicing is seen as foundational for continuous audit compliance, helping companies manage their compliance posture across jurisdictions [55][56] Market Position and Strategy - Vertex operates on a consumption-based model rather than a seat-based model, which aligns well with market trends [35] - The company is well-integrated into customers' ERP systems, making accuracy critical for their operations [35][36] - Vertex aims to leverage AI to enhance its offerings and maintain a competitive edge in the market [36][61] Competitive Landscape - The company acknowledges the presence of AI-native startups but believes its complex tax solutions serve a different market segment [62] - Vertex's comprehensive platform combining e-invoicing and compliance is viewed as a differentiator in the market [64] Additional Important Insights - The leadership is focused on balancing growth and investment, particularly in e-invoicing and AI capabilities [38][46] - There is a recognition of the need for ongoing adaptation to changing compliance mandates and customer needs [56][57] This summary encapsulates the key discussions and insights from the Vertex conference call, highlighting the company's strategic direction, market challenges, and growth opportunities.